BLINCYTO® REMS Safety Update

May 15, 2020

ASCO has been notified about a recent safety update relating to the drug BLINCYTO® (blinatumomab) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program. A REMS Letter for Professional Societies has been released to address the potential risks for (1) cytokine release syndrome which may be life-threatening or fatal, (2) neurological toxicities which may be severe, life-threatening, or fatal, and (3) preparation and administration errors associated with use of BLINCYTO®. More information for healthcare providers can be found on the BLINCYTO® REMS website for healthcare professionals.